The antinociceptive effect of nalbuphine and its long-acting esters in rats

被引:16
作者
Chu, KS
Wang, JJ [1 ]
Hu, OYP
Ho, ST
Chen, YW
机构
[1] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan
[2] Natl Def Med Ctr, Dept Res & Educ, Taipei, Taiwan
[3] TriServ Gen Hosp, Dept Anesthesiol, Taipei, Taiwan
关键词
D O I
10.1213/01.ANE.0000078589.90903.EF
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
A long-acting analgesic is particularly desirable in patients with long-lasting pain. In this study, we evaluated the antinociceptive effect and duration of action of three nalbuphine esters-nalbuphine propionate, enanthate, and decanoate-and observed whether these esters had a long-acting effect. Male Sprague-Dawley rats (n = 12 in each group) were used. Two studies were performed. In Study 1, we evaluated the antinociceptive effect of IM nalbuphine HCl with dosages of 0.25, 1.25, 2.5, 25, and 250 mumol/kg. In Study 2, we evaluated the antinociceptive effects of IM nalbuphine base and esters with a dosage of 25 mumol/kg. After 2.5, 25, and 250 mumol/kg IM injections, we found that nalbuphine HCl produced a dose-related antinociceptive effect with durations of action of 1.5, 2, and 4 h, respectively. After a 25 mumol/kg IM injection, the durations of action of the nalbuphine esters, nalbuphine propionate, enanthate, and decanoate were 5, 30, and 60 h, respectively. We conclude that, on an equimolar basis, nalbuphine esters produce relatively longer durations of action than nalbuphine HCl.
引用
收藏
页码:806 / 809
页数:4
相关论文
共 14 条
[1]  
[Anonymous], 2001, Goodman Gilman's
[2]  
ANSEL HC, 1999, PHARMACEUTICAL DOSAG, P31
[3]  
ANSEL HC, 1999, PHARM DOSAGE FORMS D, P397
[4]   PRODRUGS FOR IMPROVED ORAL NALBUPHINE BIOAVAILABILITY - INTERSPECIES DIFFERENCES IN THE DISPOSITION OF NALBUPHINE AND ITS ACETYLSALICYLATE AND ANTHRANILATE ESTERS [J].
AUNGST, BJ ;
MYERS, MJ ;
SHEFTER, E ;
SHAMI, EG .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1987, 38 (1-3) :199-209
[5]   PRODRUG BEHAVIOR OF NICOTINOYLMORPHINE ESTERS [J].
BROEKKAMP, CL ;
OOSTERLOO, SK ;
RIJK, HW .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1988, 40 (06) :434-437
[6]  
COHEN RI, 1993, ANESTH ANALG, V77, P533
[7]   OPIOID AGONIST-ANTAGONIST DRUGS IN ACUTE AND CHRONIC PAIN STATES [J].
HOSKIN, PJ ;
HANKS, GW .
DRUGS, 1991, 41 (03) :326-344
[8]   IMPROVEMENT OF THE ORAL BIOAVAILABILITY OF NALTREXONE IN DOGS - A PRODRUG APPROACH [J].
HUSSAIN, MA ;
KOVAL, CA ;
MYERS, MJ ;
SHAMI, EG ;
SHEFTER, E .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (05) :356-358
[9]  
Imoto H, 1996, BIOL PHARM BULL, V19, P263
[10]   NALBUPHINE [J].
SCHMIDT, WK ;
TAM, SW ;
SHOTZBERGER, GS ;
SMITH, DH ;
CLARK, R ;
VERNIER, VG .
DRUG AND ALCOHOL DEPENDENCE, 1985, 14 (3-4) :339-362